Li Fei, Wu Zhaoxia, Sui Xin
Department of Food Science, Shenyang Agricultural University, Shenyang, China.
Department of Biological and Food Engineering, Jilin Institute of Chemical Technology, Jilin, China.
J Food Biochem. 2020 Jun;44(6):e13192. doi: 10.1111/jfbc.13192. Epub 2020 Mar 23.
Biotransformation major ginsenoside into minor ginsenoside via microbial fermentation has been proposed as a viable option to produce minor ginsenoside, because of its biological activity superior to major ginsenoside. Cordyceps sinensis contains a complex enzymatic system and many ingredients with medicinal value that could be useful tools for biotransformation applications in the ginseng industry. Wild C. sinensis and Ascomycota sp. were collected from Changbai Mountain and identified. Analysis by UPLC-MS and HPLC indicates that the underlying pathway of major ginsenoside Rb1 during fermentation with strains was Rb1→Rd→F2→CK and Rb1→Rd→Rg3. C. sinensis and Ascomycota sp. can be applied to minor ginsenoside preparation in the food and medical industries. The antihyperlipidemic effects of Rb1 were further screened from fermentation in larvae zebrafish based on the fluorescence intensity. In the adult zebrafish model, treatment with high-dose ginsenoside Rb1 group exhibited a significant decrease in the plasma total cholesterol (TC) and triglyceride (TG) levels by 36.49% (p < .05) and 29.97% (p < .05), respectively, compared with high cholesterol group (HC). Furthermore, ginsenoside Rb1 treatment decreased the mRNA levels of LDLR and SREBP2 in the adult zebrafish liver. Ginsenoside Rb1 diet supplement significantly increased the mRNA expression of HMGCR and CYP7A1. These results suggest that ginsenoside Rb1 attenuates hypercholesterolemia via the downregulation of cholesterol synthesis and assembly or secretion of lipoproteins as well as the upregulation of cholesterol transport and efflux, providing a novel idea of ginsenoside keeping cholesterol levels down for the clinical application. PRACTICAL APPLICATIONS: Wild Cordyceps sinensis has the potential to be applied to the preparation for minor ginsenoside. Furthermore, the final fermentation product has more functional characteristics, including cordyceps acid, cordycepin, and adenosine. Wild Cordyceps sinensis and Ascomycota sp. could potentially be employed in the food and medical industries.
通过微生物发酵将主要人参皂苷转化为次要人参皂苷已被认为是生产次要人参皂苷的一种可行选择,因为其生物活性优于主要人参皂苷。冬虫夏草含有复杂的酶系统和许多具有药用价值的成分,这些可能是人参产业生物转化应用的有用工具。从长白山采集并鉴定了野生冬虫夏草和子囊菌属菌株。超高效液相色谱-质谱联用仪(UPLC-MS)和高效液相色谱(HPLC)分析表明,菌株发酵过程中主要人参皂苷Rb1的潜在转化途径为Rb1→Rd→F2→CK和Rb1→Rd→Rg3。冬虫夏草和子囊菌属菌株可应用于食品和医药行业的次要人参皂苷制备。基于荧光强度,从斑马鱼幼体发酵中进一步筛选了Rb1的降血脂作用。在成年斑马鱼模型中,与高胆固醇组(HC)相比,高剂量人参皂苷Rb1组治疗后血浆总胆固醇(TC)和甘油三酯(TG)水平分别显著降低36.49%(p<0.05)和29.97%(p<0.05)。此外,人参皂苷Rb1处理降低了成年斑马鱼肝脏中低密度脂蛋白受体(LDLR)和固醇调节元件结合蛋白2(SREBP2)的mRNA水平。人参皂苷Rb1饮食补充剂显著增加了3-羟基-3-甲基戊二酰辅酶A还原酶(HMGCR)和细胞色素P450 7A1(CYP7A1)的mRNA表达。这些结果表明,人参皂苷Rb1通过下调胆固醇合成、脂蛋白组装或分泌以及上调胆固醇转运和流出,减轻高胆固醇血症,为临床应用中人参皂苷降低胆固醇水平提供了新思路。实际应用:野生冬虫夏草有潜力应用于次要人参皂苷的制备。此外,最终发酵产物具有更多功能特性,包括虫草酸、虫草素和腺苷。野生冬虫夏草和子囊菌属菌株可能应用于食品和医药行业。